Evidence map›Paper›PMID 39075118›Full record

ArticleScientific reports2024

Peripheral inflammation is associated with brain atrophy and cognitive decline linked to mild cognitive impairment and Alzheimer's disease.

Nuanyi Liang, Kwangsik Nho, John W Newman, Matthias Arnold, Kevin Huynh, Peter J Meikle, Kamil Borkowski, Rima Kaddurah-Daouk, Alzheimer’s Disease Metabolomics Consortium

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Transcriptomic and Neuroimaging Decoding of Brain-Immune Crosstalk in Thyroid Eye Disease.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  7. Review
  8. Article
  9. Modulation of Cognitive Function by TRPM3 Channels in the Dentate Gyrus of a Menopausal Rat Model: Effects of Naringenin Treatment and Ciliary Neurotrophic Factor.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2026
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. The association of common infectious exposures with cognitive performance in community-dwelling older adults.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Nuanyi LiangWest Coast Metabolomics Center, Genome Center, University of California-Davis, Davis, CA, 95616, USA.
Kwangsik NhoDepartment of Radiology and Imaging Sciences and the Indiana Alzheimer Disease Center, Indiana University School of Medicine, Indianapolis, IN, 46202, USA.
John W NewmanWest Coast Metabolomics Center, Genome Center, University of California-Davis, Davis, CA, 95616, USA.
Matthias ArnoldDepartment of Psychiatry and Behavioral Sciences, Duke University, Durham, NC, 27708, USA.
Kevin HuynhBaker Heart and Diabetes Institute, Melbourne, VIC, 3004, Australia.
Peter J MeikleBaker Heart and Diabetes Institute, Melbourne, VIC, 3004, Australia.
Kamil BorkowskiWest Coast Metabolomics Center, Genome Center, University of California-Davis, Davis, CA, 95616, USA. kborkowski@ucdavis.edu.
Rima Kaddurah-DaoukDepartment of Psychiatry and Behavioral Sciences, Duke University, Durham, NC, 27708, USA. rima.kaddurahdaouk@duke.edu.
Alzheimer’s Disease Metabolomics Consortium

Funding

Project 4 - Mechanistic studies on the role of the gut microbiome in models for Alzheimer's diseaseU19AG063744 · NIA · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI Rima F Kaddurah-Daouk · 2019 to 2026
$54.1M
Peripheral and Central Biomarkers of Alzheimer's Disease in Diverse CohortsU19AG074879 · NIA · MAYO CLINIC JACKSONVILLE · PI Minerva Maria Carrasquillo, NILUFER ERTEKIN-TANER · 2023 to 2026
$42.0M
UC Davis Alzheimer's Disease Research CenterP30AG072972 · NIA · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Charles DeCarli, Rachel A Whitmer · 2021 to 2026
$25.2M
KBASE2: Korean Brain Aging Study, Longitudinal Endophenotypes and Systems BiologyU01AG072177 · NIA · INDIANA UNIVERSITY INDIANAPOLIS · PI LEE, DONG YOUNG, NHO, KWANGSIK TIMOTHY · 2021 to 2025
$11.2M
Metabolomic Signatures for Disease Sub-classification and Target Prioritization in AMP-ADU01AG061359 · NIA · DUKE UNIVERSITY · PI KADDURAH-DAOUK, RIMA F, KASTENMULLER, GABI · 2018 to 2022
$10.0M
Metabolic Signatures Underlying Vascular Risk Factors for Alzheimer-type DementiasRF1AG051550 · NIA · DUKE UNIVERSITY · PI KADDURAH-DAOUK, RIMA F, KLING, MITCHEL ALLAN · 2015 to 2016
$6.3M
Metabolic Networks and Pathways Predictive of Sex Differences in AD Risk and Responsiveness to TreatmentRF1AG059093 · NIA · DUKE UNIVERSITY · PI BRINTON, ROBERTA EILEEN, CHANG, RUI · 2018 to 2018
$5.9M
Metabolic Networks and Pathways in Alzheimer's DiseaseR01AG046171 · NIA · DUKE UNIVERSITY · PI KADDURAH-DAOUK, RIMA F · 2014 to 2017
$4.4M
Metabolic Network Analysis of Biochemical Trajectories in Alzheimer's DiseaseRF1AG057452 · NIA · DUKE UNIVERSITY · PI KADDURAH-DAOUK, RIMA F, KASTENMULLER, GABI · 2017 to 2017
$3.5M
Gut Liver Brain Biochemical Axis in Alzheimer's DiseaseRF1AG058942 · NIA · DUKE UNIVERSITY · PI KADDURAH-DAOUK, RIMA F, VAN DUIJN, CORNELIA MARJA · 2018 to 2018
$3.4M
ROLE OF HFE65 PROTEINS IN ALZHEIMER'S DISEASE.R01AG015903 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI GUENETTE, SUZANNE Y · 2000 to 2009
$2.9M
Metabolic age to define influences of the lipidome on brain aging in Alzheimer's diseaseR01AG081322 · NIA · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI Matthias Arnold, Rima F Kaddurah-Daouk · 2023 to 2026
$2.6M
National Health and Medical Research Council of Australia 2009965NIA NIH HHS 1R01AG081322NIA NIH HHS 3U19AG063744-04S1NIA NIH HHS FNIH: #DAOU16AMPANIA NIH HHS NIA R01AG046171NIA NIH HHS P30 AG072972NIA NIH HHS R01 AG015903NIA NIH HHS R01 AG046171NIA NIH HHS R01AG059093NIA NIH HHS R01 AG081322NIA NIH HHS RF1 AG051550NIA NIH HHS RF1AG051550NIA NIH HHS RF1 AG057452NIA NIH HHS RF1AG057452NIA NIH HHS RF1 AG058942NIA NIH HHS RF1AG058942NIA NIH HHS RF1 AG059093NIA NIH HHS U01 AG061359NIA NIH HHS U01AG061359NIA NIH HHS U01 AG072177NIA NIH HHS U19 AG063744NIA NIH HHS U19AG063744NIA NIH HHS U19 AG074879NIH HHS P30AG072972NIH HHS R01 LM012535NIH HHS U01 AG072177NIH HHS U19AG074879NLM NIH HHS R01 LM012535United States Department of Agriculture Project 2032-51530-025-00D
6 · The paper itself

Abstract

Inflammation is an important factor in Alzheimer's disease (AD). An NMR measurement in plasma, glycoprotein acetyls (GlycA), captures the overall level of protein production and glycosylation implicated in systemic inflammation. With its additional advantage of reducing biological variability, GlycA might be useful in monitoring the relationship between peripheral inflammation and brain changes relevant to AD. However, the associations between GlycA and these brain changes have not been fully evaluated. Here, we performed Spearman's correlation analyses to evaluate these associations cross-sectionally and determined whether GlycA can inform AD-relevant longitudinal measurements among participants in the Alzheimer's Disease Neuroimaging Initiative (n = 1506), with additional linear models and stratification analyses to evaluate the influences of sex or diagnosis status and confirm findings from Spearman's correlation analyses. We found that GlycA was elevated in AD patients compared to cognitively normal participants. GlycA correlated negatively with multiple concurrent regional brain volumes in females diagnosed with late mild cognitive impairment (LMCI) or AD. Baseline GlycA level was associated with executive function decline at 3-9 year follow-up in participants diagnosed with LMCI at baseline, with similar but not identical trends observed in the future decline of memory and entorhinal cortex volume. Results here indicated that GlycA is an inflammatory biomarker relevant to AD pathogenesis and that the stage of LMCI might be relevant to inflammation-related intervention.

Indexed as

Alzheimer DiseaseAtrophyBrainCognitive DysfunctionInflammationAgedAged, 80 and overBiomarkersCross-Sectional StudiesFemaleGlycoproteinsHumansMagnetic Resonance ImagingMaleBiomarkersGlycoproteinsAlzheimer’s diseaseBrain atrophyGlycAInflammationInflammatory biomarkerMetabolomicsMild cognitive impairmentPeripheral-central connectionPopulation heterogeneitySex differences

Identifiers

PMID39075118
PMCPMC11286782

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.